Executive Summary
Varex Imaging Corporation (NASDAQ: VREX) announced strong financial results for its fourth quarter and full fiscal year 2025, demonstrating significant year-over-year growth. The company reported Q4 revenues of $229 million, an 11% increase compared to the same period last year. This performance was largely propelled by a 25% surge in its industrial segment sales. The full fiscal year 2025 concluded with a non-GAAP earnings per share of $0.90, reflecting a positive turn from the challenges reported in the previous quarter.
The Event in Detail
In its earnings call on November 18, 2025, Varex management detailed the components of its Q4 performance and provided guidance for the upcoming quarter. Key financial metrics and projections from the call include:
- Gross Margin: Expected non-GAAP gross margin to be between 32% and 33%.
- Operating Expenses: Projected non-GAAP operating expenses of approximately $51 million.
- Interest and Other Expenses: Forecasted to be in the range of $9 million to $10 million.
- Tax Rate: An anticipated tax rate of about 25% for the fourth quarter.
This quarter's results stand in contrast to the third quarter of 2025, which saw a revenue decline attributed to economic challenges and geopolitical tensions. The strong finish to the fiscal year suggests resilience in the company's core business, particularly within its industrial applications.
Market Implications
The robust performance of the industrial division is a significant indicator of Varex's successful market strategy and diversification. While the medical segment remains a core component of its business, the 25% growth in industrial sales highlights the company's ability to capitalize on opportunities in sectors such as cargo screening, food inspection, and non-destructive testing. This result may help restore investor confidence, which was previously dampened by the revenue dip in Q3. The market will closely watch how Varex's stock (VREX) performs in response to this positive earnings report and the forward-looking guidance.
During the earnings call, management provided insight into its long-term strategic vision, particularly concerning its investment in photon-counting technology. The company stated its expectation to generate approximately $150 million in photon-counting revenue by 2029. This revenue is projected to be split between its primary segments:
"...we would be expecting, say, $150 million or so in photon counting revenue with, say, 2/3 of that approximately from the Medical segment and 1/3 from the Industrial segment."
This long-range forecast underscores a strategic pivot towards higher-growth, next-generation technologies. Analysts on the call focused on the drivers of the current quarter's growth, questioning whether the outperformance was primarily from the medical or industrial side, given the industrial segment had been tracking steadily around $60 million in previous quarters.
Broader Context
Varex's Q4 2025 earnings report demonstrates a significant rebound and highlights the company's operational resilience. After navigating a challenging Q3 marked by global uncertainty, the firm's strong liquidity and strategic debt management have enabled a swift recovery. The pronounced growth in the industrial segment, coupled with a clear, long-term strategic investment in photon-counting technology, positions Varex to compete effectively in both the medical and industrial imaging markets. This strategy suggests a dual focus on reinforcing its established market presence while simultaneously pursuing high-margin, emerging technologies for future growth.
